ArticleTranslational cancer research2025
Prognostic characteristics and recurrence patterns of grade 1 endometrial carcinoma: a large retrospective analysis of a tertiary center.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic characteristics, recurrence patterns and survival outcomes of uterine papillary serous carcinoma: a single-centre retrospective cohort study.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial cancer (EC) is the most common tumour of the female reproductive system, and low-grade EC is the histological type with the best prognosis for its less aggressiveness. Abnormal uterine bleeding is one of the first symptoms that appears and that allows an early diagnosis, while the disease is still confined into the uterus. The objective of this study was to identify risk factors associated with recurrence in low-grade EC across International Federation of Gynaecology and Obstetrics (FIGO) 2009 stages I to IV. Methods: This is a retrospective study that collected patients surgically treated at the Thames Valley Cancer Centre from March 2010 to January 2020 for low-grade EC. All cases were debated at the multidisciplinary team discussion, both prior to and following surgery, to decide the surgical approach and the need for adjuvant treatments. Clinical, surgical and histopathological data were gathered from electronic patient record and used for the statistical analysis. Results: A total of 238 patients were included. Overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) were favourable, with follow-up nearing 10 years. However, 14 patients (5.88%) experienced recurrence, 11 of whom (78.5%) were initially diagnosed at stage I. The median time from surgery to relapse was 30 months. The vaginal vault was the most common site of recurrence (42%), followed by pelvic lymph nodes and distant metastases. Only myometrial invasion (P=0.049) and serosal involvement (P=0.01) were statistically significant predictors of recurrence in both univariate and multivariate analyses. Conclusions: This study confirms that deep myometrial invasion and serosal involvement are significant predictors of recurrence and poor outcomes in grade 1 EC. Other factors, such as lymphovascular space invasion and lymph node positivity, were not confirmed as significant. Before recommending adjuvant treatment for low-grade EC patients exhibiting these risk factors, further prospective trials are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.